

Electronic Acknowledgement Receipt

EFS ID:	1053365
Application Number:	10518817
Confirmation Number:	9954
Title of Invention:	New use of pyrimidine - or triazine - 2 carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
First Named Inventor:	Andrew Bailey
Customer Number:	22466
Filer:	Jianzhong Shen
Filer Authorized By:	
Attorney Docket Number:	100727-1P US
Receipt Date:	22-MAY-2006
Filing Date:	20-DEC-2004
Time Stamp:	13:37:28
Application Type:	U.S. National Stage under 35 USC 371
International Application Number:	

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1		100727USAmdement.pdf	102992	yes	8

	Multipart Description		
	Doc Desc	Start	End
	Amendment After Final	1	1
	Claims	2	6
	Applicant Arguments/Remarks Made in an Amendment	7	8

Warnings:	
Information:	
Total Files Size (in bytes):	102992

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.